Yet Hong Khor Australia

Associate Professor Yet Hong Khor is a NHMRC emerging leadership research fellow at Monash University, as well as the Lead for Austin Health Oxygen Service and a specialist at the Austin and Alfred Health Interstitial Lung Disease (ILD) Services. In addition to dual clinical training in respiratory and sleep medicine, she completed a NHMRC-funded PhD in ILD and oxygen therapy at the University of Melbourne in 2019, and a post-doctoral fellowship at the University of British Columbia funded by an Australian Endeavour Leadership Award. She leads investigator-initiated clinical research programs, focusing on risk prediction and management in ILD, quality improvement in oxygen therapy delivery, and qualitative evaluation of patient care. She is an associate editor of the ILD Section for European Respiratory Journal. She has been a panelist on multiple national and international guidelines on interstitial lung disease and chronic respiratory diseases.
Job Title
Respiratory and Sleep Physician
Faculty / Department / Division
Respiratory Medicine
Institution / Organisation
Monash University; Austin & Alfred Health

22 November 2026, Sunday

Time Session
12:00
13:00
Irfhan Ali Hyder Ali Chairperson Malaysia
Justin Yu Kuan Tan Chairperson Malaysia
  • Pang Yong Kek Speaker Malaysia
    S34 - Haematological Disorder and Lungs By Yong Kek, Pang Following allogeneic haematopoietic stem cell transplantation (alloHSCT), pulmonary graft-versus-host disease (pGVHD) represents a serious complication driven by alloreactive donor immune cells, conditioning therapies, and infections. Acute manifestations present within 100 days primarily as pneumonia or bronchitis, whereas chronic pGVHD manifests beyond 100 days as bronchiolitis obliterans syndrome (BOS), interstitial lung disease (ILD), or rare vascular complications. Chronic pGVHD has an estimated cumulative incidence of ~20% within two years post-transplant, with BOS accounting for 56.4% and ILD for 30.8% of non-infectious complications. Because clinical onset is often indolent—and many patients are identified only after 40% to 50% of lung function is lost—early detection through structured surveillance is essential to prevent progressive, irreversible injury. Surveillance protocols recommend baseline and routine spirometry at 3 months, 6 months, and annually for 2 years post-transplant, with accelerated testing after acute flares or immunosuppression tapering. Patients with chronic pGVHD warrant spirometry at least every 6 months and annual full pulmonary function testing. Complementary assessments, including high-resolution CT (HRCT), 6-minute walk tests, and multidisciplinary reviews, are critical to exclude alternative pathologies and guide therapy.
  • Yet Hong Khor Speaker Australia
    Connective tissue diseases (CTDs) are increasingly prevalent, with lung involvement being common, which contributes to substantial morbidity and mortality. Lung involvement in CTD encompasses a broad spectrum of manifestations affecting the airways, lung parenchyma, pleura, pulmonary vasculature and respiratory muscles. Interstitial lung disease (ILD) represents one of the most frequent and clinically significant manifestations. Importantly, lung involvement may precede extra-pulmonary manifestations of CTD, creating diagnostic challenges for respiratory physicians. This presentation will provide a practical overview of the relationship between CTD and lung disease, with a particular focus on CTD-associated ILD. Management principles will also be explored, including multidisciplinary care models and the importance of tailoring treatment according to disease stage, underlying inflammatory and fibrotic mechanisms, and treatment goals. Bronchiolar disease and treatment-related pulmonary complications in CTD will be highlighted. The discussion aims to equip clinicians with practical strategies for the diagnosis and management of CTD-related lung disease in clinical practice.
  • Lalitha Pereirasamy Speaker Malaysia
    COPD and cardiovascular disease (CVD) frequently coexist and amplify each other, yet are usually managed separately. They share risk factors such as smoking, ageing and air pollution. Around half of COPD deaths are cardiovascular, and 7–30% of patients with acute myocardial infarction (AMI) have COPD. This presentation brings together recent reviews, a 24-study systematic review, and key cohort and trial data on the mechanisms linking COPD and CVD. It focuses on systemic inflammation and shared biomarkers. COPD confers a risk of major adverse cardiovascular events comparable to diabetes (adjusted HR 1.50 vs 1.41). It nearly triples heart failure risk, with the greatest excess in younger patients. The continuum begins early: low or declining FEV₁, even within normal limits, predicts heart failure, atrial fibrillation and stroke. Five bridges link the organs: systemic inflammation, hypoxaemia, pulmonary vascular remodelling, hyperinflation and autonomic dysfunction. Lung injury activates NF-κB and the NLRP3 inflammasome. IL-1β, IL-6, IL-8 and TNF-α then spill into the circulation, driving endothelial dysfunction, platelet activation and plaque instability. Exacerbations act as a “second hit”: cardiovascular event risk rises 22-fold during severe exacerbations, and AMI risk is eightfold in the first three days. IL-1 blockade is a promising shared target but remains untested in patients with both conditions. Conclusion :NT-proBNP, troponin, coronary artery calcium on chest CT and spirometry are ready for routine use. CRP, fibrinogen, neutrophil-to-lymphocyte ratio and heart rate variability are useful adjuncts. Every exacerbation should be treated as a cardiovascular risk window, with integrated pulmonology–cardiology care.
  • Q&A
Ballroom 2, Lower Ground Floor